Protalix BioTherapeutics, Inc. (PLX): Cost of Revenue
$26.99M
Year ended 2025-12-31
$24.83M
Trailing 12 months to 2026-06-30
+11.3%
3-year compound annual growth
+19.9%
5-year compound annual growth
+43.5%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $26.99M | +11.0% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $24.32M | +5.8% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $22.98M | +17.3% | 2026-03-18, From 2023-01-01 |
| 2022-12-31 | $19.59M | +19.8% | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | $16.35M | +50.4% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $10.87M | -0.2% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $10.89M | +17.1% | 2022-03-31, From 2019-01-01 |
| 2018-12-31 | $9.30M | -38.9% | 2021-03-30, From 2018-01-01 |
| 2017-12-31 | $15.23M | +81.4% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $8.40M | n/m | 2019-03-18, From 2016-01-01 |
| 2015-12-31 | $730.0K | +15.9% | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | $630.0K | n/a | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $0 | -100.0% | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | $8.14M | +434.0% | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | $1.52M | -65.2% | 2014-03-13, From 2011-01-01 |
| 2010-12-31 | $4.38M | +22.6% | 2013-02-28, From 2010-01-01 |
| 2009-12-31 | $3.58M | n/a | 2012-02-27, From 2009-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $26.99M | +11.0% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $30.90M | +8.8% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $26.0K | -96.9% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $39.21M | -16.7% |
| Compugen Ltd (CGEN) | 2025-12-31 | $9.25M | +16.7% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $70.95M | +56.8% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $96.37M | +746.3% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $5.76M | +622.3% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $10.60M | -36.5% |
Compare PLX, CSBR, VIR, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗